31 January 2025
: Case report 
Rhabdomyolysis of Infectious Etiology with Creatine Kinase Above One Million: A Case Report
Unusual clinical course, Challenging differential diagnosis
Marshall Weber ABCDEF 1,2, William Goss BCDE 1, Colton Hoffer BCDEF 2,3, Joseph Ogunsulire CDEG 4, Ferdinand Schafer ADE 1*DOI: 10.12659/AJCR.946364
Am J Case Rep 2025; 26:e946364
Table 3. Cases of rhabdomyolysis with CK >1 000 000.
| Age and sex | Etiology | Max CK (IU/L) | Length of HD |
|---|---|---|---|
| 28M | Coxsackie B4 []19 | 5 366 100 | Unknown |
| 30M | Influenza A []20 | 4 312 211 | Patient died |
| 22M | Sickle-cell trait, dietary supplement (synephrine), exertion []21 | 2 800 000 | 6 weeks |
| 22M | Varicella zoster virus []8 | 1 977 600 | 3 weeks |
| 3M | Viral myositis []3 | 1 778 856 | No AKI |
| 30sM | COVID-19 []4 | 1 615 500 | No AKI |
| 25M | Exertion []5 | 1 454 952 | No AKI |
| 41M | CPT-II deficiency, exertion []22 | 1 360 365 | 48 days |
| 27 M | Our case (coxsackie B3) | 1 353 105 | 20 days |
| 37M | Influenza A, sickle-cell trait []23 | 1 172 440 | 10 days |
| 36M | spp., cocaine []24 | > 1 000 000 | 1 month |
| CK – creatine kinase; M – male; HD – hemodialysis; AKI – acute kidney injury; COVID-19 – coronavirus disease 2019; CPT-II – carnitine palmitoyl transferase II. | |||